Ensysce Biosciences, Inc.

ENSC Nasdaq SEC CIK 1716947
Follow Ensysce Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $2.2M +342.4% vs same quarter last year
Net income −$82.1M −2102% vs same quarter last year
EPS, diluted −$4.52 −250.4% vs same quarter last year
Operating cash flow −$1.4M +25.2% vs same quarter last year
Revenue by quarter
$1.3M
$1.3M
$1.4M
$493.1K
$1.9M
$961K
$1.2M
$2.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$30M−$20M−$10M$0$10MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$5.1M−$10.2M
FY24$5.2M−$8M
FY23$2.2M−$10.6M
FY22$2.5M−$24.2M
FY21$3.5M−$29.1M
FY20$3.9M$4.3M
FY19-−$1.1M
FY18--
FY17--
MarginsShare of revenue
  • Operating margin
  • Net margin
−1000%−500%0%500%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−202.1%−200.8%
FY24−129.2%−153.3%
FY23−480.5%−476.4%
FY22−959.9%−959.3%
FY21−562.7%−825.4%
FY20−41%109.7%
FY19--
FY18--
FY17--
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Ensysce Biosciences
  • Healthcare median
−1000%−500%0%500%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearEnsysce BiosciencesHealthcare median
FY25−200.8%−30.6%
FY24−153.3%−47%
FY23−476.4%−58%
FY22−959.3%−80.4%
FY21−825.4%−71.8%
FY20109.7%−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%